Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024623 (gastric cancer)
 36,219 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We report herein the clinical events seen in two longterm survivors of gastric cancer with unresectable synchronous hepatic metastases. Partial gastrectomy was performed against the primary lesion and continuous intra-arterial infusion of anti-tumor drugs, followed by prolonged systemic antitumor drug treatment, were prescribed. A 43-year-old man with moderately-differentiated tubular adenocarcinoma had an uneventful course during his first 21 postoperative months. However, multiple liver metastases became manifest at 24 months and enlargement of the intrahepatic foci led to death 27 months after gastrectomy. A 51-year-old woman with moderately-differentiated tubular adenocarcinoma had an uneventful postoperative course and is now well with no signs of recurrence 6 years and 6 months after gastrectomy.
 ...
PMID:Gastric cancer with synchronous unresectable hepatic metastasis and a positive response to chemotherapy--report of two cases. 368 39

Comparative cellular DNA content measurements have been done on two sites differing from each other in their anatomical location, in 16 cases of gastric cancer by means of microphotometry. In addition, comparisons on the DNA stemline of the original gastric lesions and their metastatic lesions (8 cases of liver metastases and 9 cases of lymph node metastases) also were done. The main stemlines in four cases (25%) out of 16 gastric cancers exhibited different main DNA stemlines from the other sites in the same lesion, although in the other 12 cases examined, two sites showed the same DNA stemlines to each other. In almost all cases, the DNA stemlines of the metastatic foci were consistent with those of the original lesions. The lymph node metastases simulated the original lesions in its DNA stemlines (89%) more than did the cases of livermetastases (63%). In an exceptional case, the original lesion exhibited two definite stemlines (2C & 3.5C), but only one (2C) was recognizable in the metastatic focus of the liver. This difference indicates the probable role of "clonal selection" in a blood-borne metastasis.
 ...
PMID:[Comparative studies on the DNA content of human gastric cancer cells and its metastatic foci]. 369 7

In an attempt to define the mechanism of weight loss in cancer patients, fat and carbohydrate oxidation rates were calculated in 93 patients. Seventy patients with colorectal or gastric cancer were compared with a control group of 23 patients with nonmalignant illness. Twenty-seven patients with cancer and 13 control patients had lost more than 10% of their pre-illness body weight. Fat and carbohydrate oxidation rates were derived from measurements of oxygen consumption, carbon dioxide production, and urinary nitrogen excretion. Patients with cancer had significantly higher fat oxidation rates (p less than 0.01) and significantly lower carbohydrate oxidation rates (p less than 0.05) when compared with controls. Weight-losing cancer patients had significantly higher fat oxidation rates when compared with weight-stable cancer patients (p less than 0.02), weight-stable controls (p less than 0.01), and weight-losing controls (p less than 0.02). Cancer patients with liver metastases (N = 14) had significantly higher fat oxidation rates (p less than 0.01) and significantly lower carbohydrate oxidation rates (p less than 0.01) compared with cancer patients who had localized disease. There were no significant differences among the groups with respect to resting energy expenditure when expressed as kilocalorie per kilogram lean body mass per day. The presence of cancer appears to be associated with abnormal fat and carbohydrate metabolism. The increased rate of fat oxidation seen in patients with cancer, especially those with weight loss or liver metastases, may be a significant factor in the development of cancer cachexia.
 ...
PMID:The oxidation of body fuel stores in cancer patients. 378 35

The purpose of this study was to catagorize the metastatic patterns of advanced gastric cancer into liver and peritoneal metastases from the stromal behavior of the primary lesion in 278 patients. According to our data, peritoneal disseminations were encountered 5.0% of the medullary type, 30.0% of the intermediate type and 38.0% of the scirrhous type, while the corresponding figures for liver metastases were 28.8%, 6.0% and 1.9%, respectively. The differences among the three types were significant with both patterns of metastasis. From the present data, we assume that the histological pattern in the stroma of primary gastric cancer shows the biological behavior of cancer growth and metastatic patterns, particularly in close relation to peritoneal dissemination and liver metastases.
 ...
PMID:[The metastatic patterns of gastric cancer from its histopathological characteristics in the primary lesion--particularly in relation to peritoneal dissemination and liver metastases]. 408 85

During the period from Jun. 1973 to Dec. 1981, seven hundred and three patients with primary gastric cancer have undergone gastrectomy at the Surgical Department, Research Institute for Nuclear Medicine & Biology, Hiroshima University. As adjuvant immunochemotherapy, large dose of Mitomycin C was routinely administered; 20 mg on the day of gasrectomy and additional 10 mg on the next day, intravenously. Furthermore, PS-K, a protein-bound polysaccharide, and/or Tegafur were administered for a prolonged period of time. Two hundred and forty of 703 patients were non-curatively resected cases. The factors by which gastrectomy was limited to non-curative resection at the primary gastrectomy were peritoneal dissemintions, liver metastases or invasions to the contiguous organs. Of the 244 patients, 17 were re-laparotomized and at the same time the evaluation of the chemotherapeutic effects was investigated. Of these 17, six patients were administered with large dose OK-432, preparation of Bac. streptococcus hemolyticus, intratumorally or intraperitoneally. In three patients, Intraabdominal patching with Adriamycin (ADM) was performed the direct cytocidal activities and strong stickiness of this drug to the malignant cells. From the findings of relaparotomy, it was suggested that large dose OK-432 administration or ADM patching was effective for peritoneal disseminations.
 ...
PMID:[Evaluation of chemotherapy for resected stomach cancer: second-look operation]. 641 15

Twenty-four eligible and evaluable patients with measurable liver metastases from gastric cancer were treated with oral or rectal Tegafur. Objective responses were seen in 8 of the patients (33.3%), lasting between 1.5 and 15 months. The median survival period was 10 months for the responders and 2.6 months for non-responders. No complete response was observed. The survival of responders was significantly longer than that of non-responders (p less than 0.01). Toxicity was mild and consisted principally of gastrointestinal and hematological side effects. No central nervous system toxicity was seen.
 ...
PMID:Phase II study of orally and rectally administered Tegafur in liver metastases from gastric carcinoma. 642 66

Eighty-four patients with advanced gastric cancer treated in four centres in Scotland between June 1980 and December 1982 were reviewed following treatment with 5-fluorouracil, adriamycin and mitomycin-C (FAM). Eighty-one patients were evaluable. Twenty-eight patients (35 per cent) responded (four complete) with a median duration of response of 10.5 months and median survival of 17 months. Ten are still alive. Response was associated with an improvement in performance status. Eight patients (10 per cent) had stable disease with a median survival of 10 months. Forty-five (55 per cent) had progressive disease with a median survival of 4.5 months; one patient remains alive. Analysis of prognostic variables indicated that the presence of hepatic metastases had a negative influence on response to FAM (P less than 0.001). Treatment was well tolerated on an outpatient basis. FAM offers good palliative therapy in a proportion of patients with this disease, especially those without overt liver metastases.
 ...
PMID:Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C. 654 66

The sonographic images obtained in 32 patients with known gastric cancer, who were referred to sonography for evaluation of liver metastases and in whom a specific attempt was made in order to visualize the tumor, were reviewed and evaluated for the extent of exogastric neoplasm. Surgical correlation was available in 21 cases. Sonography allowed identification in five of seven patients who had distant metastases, 12 of 15 who had lymphadenopathy, and nine of 12 patients who had direct spread to structures surrounding the tumor; ascites was always correctly identified. In only one case, a false-positive diagnosis of lymph nodes metastases was made. These results indicate that sonography has good specificity in the staging of gastric cancer and that, when patients are referred for evaluation of liver metastases, it is worthwhile to gather useful additional information about tumor extent by performing a complete sonographic examination of the abdomen and pelvis and by making an attempt to visualize the primary neoplasm and its relations to surrounding organs.
 ...
PMID:Sonographic staging of gastric cancer. 660 Mar 41

The prognostic value of pretreatment information relating to prior treatment, demography, physical status, symptoms, disease involvement, pathologic, immunologic, and clinical chemistries were analyzed for a series of 322 patients with advanced gastric cancer. All patients received chemotherapy upon entry into Gastrointestinal Tumor Study Group protocols which were active between 1975 and 1978. Multivariate models were used to study relationships between prognostic factors and survival for all patients and objective tumor resonse for a subset of 137 patients with measurable disease. The initial performance status was a leading determinant of survival (P less than 0.0001). In addition, new summary measures relating to blood chemistries (P less than 0.01) and differential counts (P less than 0.001) were shown to influence patient survival. Blood chemistry parameters included SGOT, total serum protein, and total direct bilirubin while differential counts included absolute granulocytes, lymphocytes, and monocytes. Thus, the initial performance status, measurable disease status, blood chemistries, and differential counts are recommended as stratification factors in the design and analysis of trials involving patients with advanced gastric cancer. The initial performance status was examined in relation to other pretreatment data. The performance status at study entry correlated independently with the degree of weight loss (P less than 0.001), blood chemistries (P less than 0.01), differential counts (P less than 0.05), and peritoneal metastases (P less than 0.05). The measurable and nonmeasurable subgroups were compared with respect to baseline characteristics. Patients with measurable disease had more liver metastases (56 versus 35%) and less peritoneal metastases (76 versus 49%) than patients with nonmeasurable disease. Controlling for the imbalance in liver and peritoneal metastases, the presence of measurable disease was less favorable than nonmeasurable disease with respect to survival. Regarding the pathways of disease spread, there was a strong correlation (P less than 0.001) between primary tumor site within the stomach and location of metastases. Diffuse lesions were associated with the lowest frequency (25%) of liver metastases. Diffuse lesions (58%) and tumors of the pyloris (54%) were associated with the highest percentage of peritoneal metastases. Tumors of the cardia or fundus were more likely to metastasize to the liver while diffuse tumors were more likely to spread to the peritoneum. Pretreatment factors under study did not appear to be the dominant factors responsible for prolongation of survival in patients with an objective tumor response. Pretreatment factors predicted a three week advantage; however, a 22 week advantage was observed for responders over nonresponders.
 ...
PMID:Studies in prognostic factors relating to chemotherapy for advanced gastric cancer. 675 15

Patients with gastric cancer and liver metastases are believed not to benefit from gastric resection. In 43 patients with strong suspicion of--or proven--gastric cancer, fit for elective, radical surgery, preoperative liver scintigraphy was performed, in an attempt to select patients with liver metastases before laparotomy. Liver scintigraphy identified 6 out of 7 patients with metastases. One patient with massive steatosis had a false-positive scintigram. Percutaneous scan-guided fine-needle aspiration biopsy verified 4 true positive scintigrams. True-positive scintigrams in 2 patients heralded a change in the planned treatment. We consider that a preoperative liver scintigraphy in a population thus selected is beneficial in the planning of treatment: only patients with a negative scan-guided fine-needle aspiration biopsy should be operated upon.
 ...
PMID:The value of liver scintigraphy in the management of patients with suspected gastric cancer. A prospective, consecutive study. 732 54


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>